Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Haematologica (Roma) 2020-12, Vol.105 (12), p.2879-2882
Hauptverfasser:	Zweegman, Sonja, Stege, Claudia A M, Haukas, Einar, Schjesvold, Fredrik H, Levin, Mark-David, Waage, Anders, Leys, Rineke B L, Klein, Saskia K, Szatkowski, Damian, Axelsson, Per, Hieu Do, Trung, Knut-Bojanowska, Dorota, van der Spek, Ellen, Svirskaite, Asta, Klostergaard, Anja, Salomo, Morten, Blimark, Celine, Ypma, Paula F, Mellqvist, Ulf-Henrik, Poddighe, Pino J, Stevens-Kroef, Marian, van de Donk, Niels W C J, Sonneveld, Pieter, Hansson, Markus, van der Holt, Bronno, Abildgaard, Niels
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Combined Chemotherapy Protocols - therapeutic use Boron Compounds Bortezomib - therapeutic use Dexamethasone - therapeutic use Glycine - analogs & derivatives Hematopoietic Stem Cell Transplantation Humans Letters to the Editor Multiple Myeloma - diagnosis Multiple Myeloma - drug therapy Stem Cell Transplantation Thalidomide - therapeutic use Transplantation, Autologous Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!